AbbVie’s ABBV stock slipped below its 50-day simple moving average (SMA) late last week. The stock has also declined by ...

The drugmaker has plenty to offer investors.

AbbVie is hoping to attract customers with an enticing program.

Discover why AbbVie (ABBV) is rated Strong Buy, with robust 2025 growth, diversified revenues, and attractive valuation.

Biogen (BIIB) stock slips as HSBC downgrades to a Sell equivalent rating as part of an analysis that included an upgrade on ...

AbbVie’s latest narrative update leaves its fair value estimate steady at roughly $243.55 per share, even as small tweaks to ...

Close to two years after AbbVie handed over $48 million for the rights to OSE Immunotherapeutics’ inflammation drug, the Big ...

Healthcare stocks have lagged the broader market for the past three years, weighed down by post-COVID earnings volatility, ...

Futures are trading modestly lower as the big day has finally arrived: the Federal Reserve will wrap up its last meeting of ...

If you are wondering whether AbbVie is still attractive after its huge run, or if you are late to the party, you are in the ...

AbbVie is seeking European approval of expanded use of its migraine drug atogepant in adults following strong results from a ...

NANTES, France, December 8th, 2025 - 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced ...